Drugs for Alpha-Thalassemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 248)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Metformin |
Approved |
Phase 4 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
2 |
|
Peginterferon alfa-2b |
Approved |
Phase 4 |
|
215647-85-1, 99210-65-8 |
|
Synonyms:
Interferon alfa-2b
Intron A
Peginterferon alfa-2b
PEGINTRON
|
PEG-INTRON
PegIntron®|Sylatron®
rIFN-alpha-2b
Unitron PEG
|
|
3 |
|
Zoledronic acid |
Approved |
Phase 4 |
|
118072-93-8 |
68740 |
Synonyms:
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonate
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonate
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
ácido zoledrónico
ACLASTA
Aclasta®|CGP-42446|CGP-42446A|Reclast®|zoledronate|Zometa®
ANHYDROUS ZOLEDRONIC ACID
CGP-42446
CGP-42446A
Novartis brand OF zoledronic acid
|
Reclast
ZERLINDA
ZOL
ZOL446
ZOLEDRONATE
Zoledronic acid
Zoledronic acid anhydrous
ZOLEDRONIC ACID HYDRATE
ZOLEDRONIC ACID MONOHYDRATE
ZOLEDRONIC ACID, ANHYDROUS
Zometa
Zometa Concentrate
|
|
4 |
|
Ledipasvir |
Approved |
Phase 4 |
|
1256388-51-8 |
67505836 |
Synonyms:
GS 5885
GS5885
GS-5885
LEDIPASVIR
|
Lédipasvir
LEDIPASVIR ACETONATE
Ledipasvirum
WHO 9796
|
|
5 |
|
Sofosbuvir |
Approved |
Phase 4 |
|
1190307-88-0 |
45375808 |
Synonyms:
GI 7977
GI-7977
GS7977
GS-7977
ISOPROPYL (2S)-2-{[(S)-{[(2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL]METHOXY}(PHENOXY)PHOSPHORYL]AMINO}PROPANOATE
PSI 7977
|
PSI-7977
PSI-7977, GS-7977
S)-ISOPROPYL 2-((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4- DIHYDROPYRIMIDIN-1(2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)- (PHENOXY)PHOSPHORYLAMINO)PROPANOATE
SOFOSBUVIR
SOVALDI
|
|
6 |
|
Zinc sulfate |
Approved, Investigational |
Phase 4 |
|
7733-02-0 |
|
Synonyms:
Zinc sulfate (anhydrous)
Zinc sulfate anhydrous
Zinc sulfate, anhydrous
|
Zinc sulphate
Zinc sulphate anhydrous
Zinc sulphate, anhydrous
|
|
7 |
|
Hyaluronic acid |
Approved, Vet_approved |
Phase 4 |
|
9004-61-9 |
53477741 |
Synonyms:
(2S,3S,4R,5R,6R)-3-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate
(2S,3S,4R,5R,6R)-3-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid
(2S,3S,4R,5R,6R)-3-{[(2S,3R,4R,5S,6R)-4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5,6-trihydroxyoxane-2-carboxylate
2-Acetamido-2-deoxy-b-D-gluco-hexopyranosyl-(1->4)-b-D-gluco-hexopyranuronate
2-Acetamido-2-deoxy-b-D-gluco-hexopyranosyl-(1->4)-b-D-gluco-hexopyranuronic acid
2-Acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-beta-D-gluco-hexopyranuronate
|
2-Acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-beta-D-gluco-hexopyranuronic acid
2-Acetamido-2-deoxy-β-D-gluco-hexopyranosyl-(1->4)-β-D-gluco-hexopyranuronate
2-Acetamido-2-deoxy-β-D-gluco-hexopyranosyl-(1->4)-β-D-gluco-hexopyranuronic acid
Hyaluronan
Hyaluronate
WURCS=2.0/2,2,1/[a2122a-1b_1-5][a2122h-1b_1-5_2*ncc/3=o]/1-2/a4-b1
|
|
8 |
|
Velpatasvir |
Approved, Investigational |
Phase 4 |
|
1377049-84-7 |
77335690 67683363 |
Synonyms:
|
9 |
|
Peginterferon alfa-2a |
Approved, Investigational |
Phase 4 |
|
198153-51-4 |
|
Synonyms:
PEGASYS
PEG-IFN alfa-2A
PEG-Interferon alfa-2A
PEGINTERFERON ALFA-2A
PEGYLATED IFN-ALPHA-2A
Pegylated Interfeaon alfa-2A
|
Pegylated interferon alfa-2a
Pegylated interferon alpha-2a
Pegylated-interferon alfa 2a
RO-258310000
ROFERON-A
|
|
10 |
|
Ribavirin |
Approved |
Phase 4 |
|
36791-04-5 |
37542 |
Synonyms:
1-b-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-b-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-Β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
1-Β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
Copegus
Copegus®|RBV|Rebetol®|ribofluranosyl carboxamide|Virazole®
Dermatech brand OF ribavirin
Essex brand OF ribavirin
Grossman brand OF ribavirin
ICN brand OF ribavirin
Merck brand OF ribavirin
NSC-163039
Pfizer brand OF ribavirin
RBV
Rebetol
Rebetron
Rebretron
Ribamide
Ribamidil
Ribamidyl
RIBAPAK
Ribasphere
RIBAV
RIBAVARIN
Ribavirin
|
Ribavirin Capsules
Ribavirin merck brand
Ribavirin Triphosphate
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirin-TP
Ribavirinum
Ribavirinum [INN-Latin]
RIBOFLURANOSYL CARBOXAMIDE
Ribovirin
RTC
RTCA
RTP
SCH 18908
SCH-18908
Three rivers pharmaceuticals brand OF ribavirin
Tribavirin
Varazid
Vilona
VIRAMID
Viramide
VIRAZID
Virazide
Virazole
Virazole 5'-triphosphate
|
|
11 |
|
Mycophenolic acid |
Approved, Investigational |
Phase 4 |
|
24280-93-1 |
446541 |
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
68618
Acid, mycophenolic
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Cellcept
ERL080
ERL-080
ERL-080|Myfortic® (mycophenolate sodium)
Melbex
Micofenolico acido
Mofetil hydrochloride, mycophenolate
Mofetil, mycophenolate
|
Mycophenoic acid
Mycophenolate
Mycophenolate mofetil
Mycophenolate mofetil hydrochloride
Mycophenolate sodium
Mycophenolate, sodium
MYCOPHENOLIC ACID
Mycophenolic acid morpholinoethyl ester
Mycophenolsaeure
Mycophenolsäure
Myfortic
NSC-129185
RS-61443 [AS MOFETIL]
Sodium mycophenolate
|
|
12 |
|
Tacrolimus |
Approved, Investigational |
Phase 4 |
|
104987-11-3 |
6473866 445643 |
Synonyms:
(-)-FK 506
Anhydrous tacrolimus
Anhydrous, tacrolimus
Cilag brand OF tacrolimus
FK5
FK506
FK-506
FK506|fujimycin|Prograf®|Protopic®
FR-900506
FUJIMYCIN
Fujisawa brand OF tacrolimus
Janssen brand OF tacrolimus
|
K506
LCP-Tacro
Prograf
Prograft
PROTOPIC
Tacarolimus
TACROLIMUS
Tacrolimus anhydrous
tacrolimus hydrate
TACROLIMUS MONOHYDRATE
Tacrolimus, anhydrous
|
|
13 |
|
Sodium citrate |
Approved, Investigational |
Phase 4 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
14 |
|
Sildenafil |
Approved, Investigational |
Phase 4 |
|
139755-83-2, 171599-83-0 |
5212 135398744 |
Synonyms:
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulphonyl)-4-methylpiperazine
1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
1-{[3-(4,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-5-YL)-4-ETHOXYPHENYL]SULFONYL}-4-METHYLPIPERAZINE
5-[2-ETHOXY-5-(4-METHYLPIPERAZIN-1-YLSULFONYL)PHENYL]-1-METHYL-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-7(6H)-ONE
5-[2-ETHOXY-5-(4-METHYL-PIPERAZINE-1-SULFONYL)-PHENYL]-1-METHYL-3-PROPYL-1,6-DIHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-7-ONE
Acetildenafil
Aphrodil
Caverta
Citrate, sildenafil
Desmethyl sildenafil
Desmethylsildenafil
HIP0908
HIP-0908
Homosildenafil
Hydroxyhomosildenafil
Lactate, sildenafil
NCX 911
|
NCX-911
NIPATRA
Nitrate, sildenafil
Revatio
Sildenafil
Sildenafil citrate
Sildenafil lactate
Sildenafil nitrate
Sildenafil Viagra
Sildenafil, desmethyl
Sildenafilo
UK-92480
UK-9248010
UK-92480-10
Viagra
Viagra®
VIZARSIN
|
|
15 |
|
Basiliximab |
Approved, Investigational |
Phase 4 |
|
179045-86-4 |
|
Synonyms:
BASILIXIMAB
CHI621
CHI-621
CHI-621|L04AC02|SDZ-CHI-621|Simulect®
|
CHIMERIC MOUSE-HUMAN ANTICD25
IG GAMMA-1 CHAIN C REGION
SDZ-CHI-621
SIMULECT
|
|
16 |
|
Methotrexate |
Approved |
Phase 4 |
|
1959-05-2, 59-05-2 |
4112 126941 |
Synonyms:
[<sup>3</sup>H]-methotrexate
2-[(4-{[(4-amino-2-imino-2,3-dihydropteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioate
4-Amino-10-methylfolate
4-Amino-10-methylfolic acid
4-Amino-N(10)-methylpteroylglutamate
4-Amino-N(10)-methylpteroylglutamic acid
ABITREXATE
Abitrexate®|amethopterin|Nordimet®|Rasuvo®
Amethopterin
Amethopterine
Antifolan
Arbitrexate
CL-14377
Dicesium salt methotrexate
EBETREX
EMT-25299
Emtexate
EMTEXATE HIGH-POT
EMTEXATE PF
Emtexic acid
FOLEX
HDMTX
Hydrate, methotrexate
L-Amethopterin
Ledertrexate
Ledertrexic acid
MAXTREX
Metatrexan
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate
Méthotrexate
Methotrexate hydrate
|
Methotrexate sodium
Methotrexate, (D)-isomer
Methotrexate, (DL)-isomer
Methotrexate, dicesium salt
Methotrexate, disodium salt
Methotrexate, sodium salt
Methotrexatum
Methotrexic acid
Methylaminopterin
Methylaminopterinum
METOJECT
Metotrexato
Mexate
MEXATE-AQ
MTX
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamate
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-Bismethylpteroylglutamic acid
NSC-740
Otrexup
OTREXUP PFS
R-9985
RASUVO
Rheumatrex
R-METHOTREXATE
Sodium, methotrexate
TCMDC-123832
TCMDC-125488
TCMDC-125858
TCMDC-125858TCMDC-125488TCMDC-123832Methotrexate
TCMDC-125858TCMDC-125488TCMDC-123832Methotrexic acid
Trexall
Xatmep
ZLATAL
|
|
17 |
|
Lactitol |
Approved, Investigational |
Phase 4 |
|
585-86-4 |
157355 |
Synonyms:
4-O-beta-D-Galactopyranosyl-D-glucitol
4-O-β-D-Galactopyranosyl-D-glucitol
D-Lactitol
Emportal
Importal
Lactitol
|
Lactitolum
Neda lactiv importal
Oponaf
Pizensy
WURCS=2.0/2,2,1/[H2122H][a2112h-1b_1-5]/1-2/a4-b1
|
|
18 |
|
Panobinostat |
Approved, Investigational |
Phase 4 |
|
404950-80-7 |
6918837 |
Synonyms:
(2E)-N-HYDROXY-3-[4-({[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO}METHYL)PHENYL]ACRYLAMIDE
FARYDAK
Farydak®|LBH-589|LBH589
LBH 589
|
LBH589
LBH-589
PANOBINOSTAT
Panobinostatum
|
|
19 |
|
Cholecalciferol |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
67-97-0, 1406-16-2 |
5280795 10883523 |
Synonyms:
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-1-CYCLOHEXANOL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENECYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-{2-[(1R,4E,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXAN-1-OL
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3BETA,Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
(3Β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
3-BETA,Z,7E-9,10-SECOCHOLESTR-5,7,10(19)-TRIEN-3-OL
7-DEHYDROCHOLESTEROL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
ACCRETE D3
ACIFEROL D3
ACTIVATED
Activated 7-dehydrocholesterol
ADCAL-D3
ARACHITOL
AVITICOL
BIOLIFE VITAMIN D3
BIO-VITAMIN D3
CACIT D3
CALCEOS
CALCICHEW D3
CALCICHEW D3 FTE
CALCICHEW D3 ONCE DAILY
CALCI-D
Calciferol
Calciol
CALDRINK D3
CALFOVIT D3
CC
Cholecalciferol
CHOLECALCIFEROL D3
Cholecalciferols
Cholecalciferolum
COLECAL D3
Colecalciferol
Colecalciferolum
COLEKAL-D3
COLEVIT D3
CUBICOLE D3
D3 LEMON MELTS
D3-50
D3-VIGANTOL
DEKRISTOL
DELSTEROL
Delta-D
DEPARAL
DESUNIN
DEVARON
Dihydrocholesterol
DLUX 400
D-MAX
D-TRACETTEN
|
D-VIT3
EBIVIT
E-D3
EVACAL D3
FERACOL
FULTIUM DAILY D3
FULTIUM-D3
GRANUVIT D3
HUX D3
INVITA D3
ISO D3
KORA LIQUID
MICRO-DEE
NATECAL D3
NATURE'S REMEDY VITAMIN D3
NEO-D
NPHD3
NSC-375571
Oleovitamin D3
OSTEOCAPS D3
PLENACHOL
PRO D3
PRO D3 FOLIC
PRO D3 FORTE
PROVITINA
QUINTOX
RICKETON
ROYALVIT D3
STEXEROL-D3
STIVIT-D3
SUNVIT-D3 1,000
SUNVIT-D3 10,000
SUNVIT-D3 2,000
SUNVIT-D3 20,000
SUNVIT-D3 3,000
SUNVIT-D3 400
SUNVIT-D3 5,000
SUNVIT-D3 50,000
SUNVIT-D3 800
SYNERVIT-D3
THEICAL D-3
THORENS
TRIVITAN
VIDDE-3-HYDROSOL
VI-DE3
VIDEKHOL
VIGANTOL
VIGANTOLETTEN
VIGANTOLETTEN 500
VIGORSAN
VIT D3 STREULI
VITA-D3
VITAMIN D
Vitamin D 3
VITAMIN D ASSAY SYSTEM SUITABILITY
Vitamin D NOS
Vitamin D, unspecified form
Vitamin D3
Vitamin D-3
VITINC DAN-DEE-3
ZYMAD
δ-D
|
|
20 |
|
Calcifediol |
Approved, Nutraceutical |
Phase 4 |
|
19356-17-3 |
5283731 |
Synonyms:
(1S,3Z)-3-{2-[(1R,3AS,4E,7AR)-1-[(2R)-6-HYDROXY-6-METHYLHEPTAN-2-YL]-7A-METHYL-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXAN-1-OL
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-3,25-diol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-3,25-diol
(3S,5Z,7E)-9,10-Seco-5,7,10(19)-cholestatriene-3,25-diol
(3S,5Z,7E)-9,10-Secocholesta-5,7,10-triene-3,25-diol
(3Β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-triene-3,25-diol
25 Hydroxycholecalciferol
25 Hydroxycholecalciferol monohydrate
25 Hydroxyvitamin D 3
25 Hydroxyvitamin D3
25(OH)D
25(OH)D3
25-Hydroxycholecalciferol
25-Hydroxy-cholecalciferol
25-Hydroxycholecalciferol monohydrate
25-Hydroxyvitamin D 3
25-Hydroxyvitamin D3
3-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexanol
5,6-cis-25-Hydroxyvitamin D3
9,10-Secocholesta-5,7,10(19)-triene-3b,25-diol
Anhydrous, calcifediol
|
Aventis brand OF calcifediol
Calcidiol
Calcifediol
Calcifédiol
Calcifediol anhydrous
Calcifediol aventis brand
Calcifediol faes brand
Calcifediol organon brand
Calcifediol, (3 alpha,5Z,7E)-isomer
Calcifediol, (3 beta,5E,7E)-isomer
Calcifediolum
Calderol
Dedrogyl
Didrogyl
Faes brand OF calcifediol
Hidroferol
Monohydrate, 25-hydroxycholecalciferol
Organon brand OF calcifediol
Rayaldee
RYALDEE
U-32070E
|
|
21 |
|
Ergocalciferol |
Approved, Nutraceutical |
Phase 4 |
|
50-14-6 |
5280793 |
Synonyms:
(+)-Vitamin D2
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(E,2R,5R)-5,6-DIMETHYLHEPT-3-EN-2-YL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENECYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(E,2R,5R)-5,6-DIMETHYLHEPT-3-EN-2-YL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(E,1R,4R)-1,4,5-TRIMETHYLHEX-2-ENYL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-1-CYCLOHEXANOL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(E,1R,4R)-1,4,5-TRIMETHYLHEX-2-ENYL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-{2-[(1R,3AS,4E,7AR)-1-[(2R,3E,5R)-5,6-DIMETHYLHEPT-3-EN-2-YL]-7A-METHYL-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXAN-1-OL
(3b,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(3Β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,secoergosta-5,7,10(19)-ol
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3ah)-indanylidene]ethylidene]-cyclohexanol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
Activated ergosterol
beta-Ol
Buco-D
Calciferol
CALCIFEROL IN ARACH OIL
Calciferols
Calciferon 2
CALTRATE
Condacaps
Condocaps
Condol
Crtron
Crystallina
D2, Vitamin
Daral
D-Arthin
Davitamon D
Davitin
Decaps
Dee-osterol
Dee-ron
Dee-ronal
Dee-roual
delta-Arthin
Deltalin
delta-Tracetten
De-rat concentrate
Deratol
Detalup
D-FORTE
Diactol
Divit urto
Doral
Drisdol
D-Tracetten
ECIFEROL D2
Ercalciol
|
Ergocalciferol
ERGOCALCIFÉROL
Ergocalciferol oil
Ergocalciferols
Ergocalciferolum
ERGO-D2
ERGORAL D2
Ergorone
Ergosterol activated
Ergosterol irradiated
Ertron
Fortodyl
Geltabs
Hi-deratol
Infron
Irradiated ergosta-5,7,22-trien-3beta-ol
LANES
Metadee
Mina D2
Mulsiferol
Mykostin
Novovitamin-D
NSC-62792
Oleovitamin D
OLEOVITAMIN D, SYNTHETIC
Oleovitamin D2
Osteil
Ostelin
OSTO-D2
Radiostol
Radstein
Radsterin
Rodine C
Shock-ferol
Shock-ferol sterogyl
Sterogyl
STEROGYL 15H
STEROGYL-15
Synthetic vitamin D
Uvesterol D
Uvesterol-D
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in oil
VITAMIN D
Vitamin D 2
Vitamin D2
Vitamina D2
Vitavel-D
|
|
22 |
|
Arginine |
Approved, Investigational, Nutraceutical |
Phase 4 |
|
74-79-3 |
6322 |
Synonyms:
(2S)-2-Amino-5-(carbamimidamido)pentanoate
(2S)-2-Amino-5-(carbamimidamido)pentanoic acid
(2S)-2-AMINO-5-(DIAMINOMETHYLIDENEAMINO)PENTANOIC ACID
(2S)-2-AMINO-5-[(DIAMINOMETHYLIDENE)AMINO]PENTANOIC ACID
(2S)-2-Amino-5-guanidinopentanoate
(2S)-2-Amino-5-guanidinopentanoic acid
(2S)-2-AMINO-5-GUANIDINO-PENTANOIC ACID
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoate
(S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
(S)-2-Amino-5-[(aminoiminomethyl)amino]-pentanoic acid
(S)-2-Amino-5-guanidinopentanoate
(S)-2-Amino-5-guanidinopentanoic acid
(S)-2-Amino-5-guanidinovalerate
(S)-2-Amino-5-guanidinovaleric acid
2-Amino-5-guanidinovalerate
2-Amino-5-guanidinovaleric acid
5-[(Aminoiminomethyl)amino]-L-norvaline
Arg
Arginina
Arginine
|
Arginine hydrochloride
Arginine, L isomer
Arginine, L-isomer
DL Arginine acetate, monohydrate
DL-Arginine acetate, monohydrate
Hydrochloride, arginine
L Arginine
L-(+)-Arginine
L-a-Amino-D-guanidinovalerate
L-a-Amino-D-guanidinovaleric acid
L-alpha-Amino-delta-guanidinovalerate
L-alpha-Amino-delta-guanidinovaleric acid
L-Arg
L-Arginin
L-ARGININE
L-Isomer arginine
Monohydrate DL-arginine acetate
N5-(Aminoiminomethyl)-L-ornithine
NSC-206269
R
|
|
23 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
24 |
|
Vaccines |
|
Phase 4 |
|
|
|
25 |
|
Interferon alpha-2 |
|
Phase 4 |
|
|
|
26 |
|
Interferon-alfa-1b |
|
Phase 4 |
|
|
|
27 |
|
Hormones |
|
Phase 4 |
|
|
|
28 |
|
Vitamins |
|
Phase 4 |
|
|
|
29 |
|
Trace Elements |
|
Phase 4 |
|
|
|
30 |
|
Micronutrients |
|
Phase 4 |
|
|
|
31 |
|
Ledipasvir, sofosbuvir drug combination |
|
Phase 4 |
|
|
|
32 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
33 |
|
Heptavalent Pneumococcal Conjugate Vaccine |
|
Phase 4 |
|
|
|
34 |
|
Calciferol |
|
Phase 4 |
|
|
|
35 |
|
Sofosbuvir-velpatasvir drug combination |
|
Phase 4 |
|
|
|
36 |
|
interferons |
|
Phase 4 |
|
|
|
37 |
|
Interferon-alpha |
|
Phase 4 |
|
|
|
38 |
|
Vitamin D2 |
|
Phase 4 |
|
|
3249 |
Synonyms:
Calciferols
D2, Vitamin
Ergocalciferol
|
Ergocalciferols
Vitamin D 2
Vitamin D2
|
|
39 |
|
Ergocalciferols |
|
Phase 4 |
|
|
|
40 |
|
Hydroxycholecalciferols |
|
Phase 4 |
|
|
|
41 |
|
Immunoglobulins, Intravenous |
|
Phase 4 |
|
|
|
42 |
|
Calcineurin Inhibitors |
|
Phase 4 |
|
|
|
43 |
|
Antitubercular Agents |
|
Phase 4 |
|
|
|
44 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
45 |
|
Phosphodiesterase Inhibitors |
|
Phase 4 |
|
|
|
46 |
|
Phosphodiesterase 5 Inhibitors |
|
Phase 4 |
|
|
|
47 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
48 |
|
Citrate |
|
Phase 4 |
|
|
|
49 |
|
Immunoglobulin Fc Fragments |
|
Phase 4 |
|
|
|
50 |
|
Cyclosporins |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 369)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalasemia Major |
Unknown status |
NCT02984475 |
Phase 4 |
Metformin |
2 |
Study of the B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals With Beta-thalassemia Major |
Unknown status |
NCT01846923 |
Phase 4 |
|
3 |
Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major |
Unknown status |
NCT03171831 |
Phase 4 |
Busulfan;Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Tacrolimus;Methotrexate;Thymoglobulin;Basiliximab |
4 |
Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study |
Unknown status |
NCT02342145 |
Phase 4 |
Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil |
5 |
A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance |
Unknown status |
NCT00103753 |
Phase 4 |
deferiprone |
6 |
The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study |
Unknown status |
NCT01323608 |
Phase 4 |
Vitamin D3;Placebo |
7 |
Investigation of Signal Pathway Induced by Colla Corri Asini Regulating Globin Level in Beta Thalassemia Patients With Pregnancy Anemia |
Unknown status |
NCT03392298 |
Phase 4 |
Colla corii asini |
8 |
Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C |
Unknown status |
NCT00887081 |
Phase 4 |
PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin |
9 |
A Multi-center Randomized, Double-blind, Placebo-controlled Study of Colla Corii Asini for the Treatment of Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency) |
Unknown status |
NCT03374111 |
Phase 4 |
Colla corii asini;a Simulate Agent of Colla corii asini granule |
10 |
Phase IV Study of the Use of Sequential DFP-DFO Versus DFP in Thalassemia Major Patients |
Completed |
NCT00733811 |
Phase 4 |
Deferiprone (DFP) and Deferoxamine (DFO);Deferiprone (DFP) |
11 |
An Epidemiological Study to Assess the Prevalence of Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) |
Completed |
NCT01736540 |
Phase 4 |
|
12 |
Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade) |
Completed |
NCT00749515 |
Phase 4 |
Deferoxamine;Deferasirox |
13 |
Increased Survival and Reversion of Iron-Induced Cardiac Disease in Patients With Thalassemia Major Receiving Intensive Combined Chelation Therapy |
Completed |
NCT00800761 |
Phase 4 |
Deferoxamine and Deferiprone;Deferoxamine |
14 |
Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia |
Completed |
NCT03095326 |
Phase 4 |
Sucrose |
15 |
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload |
Completed |
NCT00564941 |
Phase 4 |
deferasirox |
16 |
Randomized Trial Comparing the Relative Efficacy of Deferiprone to That of Deferoxamine in Removing Excess Cardiac Iron in Thalassemia Major Patients |
Completed |
NCT00105495 |
Phase 4 |
Ferriprox (deferiprone);Desferal (deferoxamine) |
17 |
1-year Extension to CICL670A2402 an Open-label, Multi-center Trial of the Efficacy and Safety of Long-term Treatment With Deferasirox (10 to 20 mg/kg/Day) in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2- Year Duration) |
Completed |
NCT00171301 |
Phase 4 |
Deferasirox |
18 |
A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation. |
Completed |
NCT01610297 |
Phase 4 |
ICL670 |
19 |
Zinc Supplementation on Cellular Immunity in Thalassemia Major |
Completed |
NCT03117192 |
Phase 4 |
Zinc Sulfate;Sucrose Syrup |
20 |
Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia |
Completed |
NCT03591575 |
Phase 4 |
Deferiprone oral solution;Placebo |
21 |
Prospective Crossover Study on Beta(ß)-Thalassaemia Transfusion-dependent to Evaluate the Impact on Transfusion Regimen of Two Pre-storage Leukoreduced PRBCs(In-line Filtration + B-C Separation; Whole Blood Filtration + B-C Conservation) |
Completed |
NCT03992001 |
Phase 4 |
|
22 |
Evaluation of Liver Fibrosis by Serum Hyalornic Acid Measurement in β-Thalassemic Children Infected With Hepatitis C Virus Before and After Direct-Acting Antiviral Therapy |
Completed |
NCT03961828 |
Phase 4 |
Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni] |
23 |
An Open Label, Multi-center, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients With Non-transfusion Dependent Thalassemia |
Completed |
NCT01709838 |
Phase 4 |
deferasirox |
24 |
Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial |
Completed |
NCT03032666 |
Phase 4 |
sofosbuvir/velpatasvir |
25 |
Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events |
Completed |
NCT00346242 |
Phase 4 |
Zoledronic Acid |
26 |
1 Year, Open-label Multicenter Evaluation of Efficacy, Safety of Deferasirox in Patients MDS, Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. |
Completed |
NCT01250951 |
Phase 4 |
Deferasirox |
27 |
A Study on PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) in Iranian Thalassemic Patients With Chronic Hepatitis C Infection |
Completed |
NCT00707850 |
Phase 4 |
PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) |
28 |
A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant |
Completed |
NCT03176849 |
Phase 4 |
|
29 |
Comparative Clinical Study Evaluating the Effect of L-arginine Versus Sildenafil in Children With Beta Thalassemia Associated With Pulmonary Hypertension |
Recruiting |
NCT03402191 |
Phase 4 |
L-arginine;Sildenafil |
30 |
Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study |
Recruiting |
NCT04009525 |
Phase 4 |
Busulfan;Cyclophosphamide;Fludarabine;Thymoglobulin;cyclosporine A;Mycophenolate mofetil;Tacrolimus;Methotrexate;Basiliximab;Ruxolitinib |
31 |
The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study |
Recruiting |
NCT05462548 |
Phase 4 |
Luspatercept Injectable Product |
32 |
Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies |
Recruiting |
NCT02386800 |
Phase 4 |
ruxolitinib;panobinostat |
33 |
An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old |
Withdrawn |
NCT01724138 |
Phase 4 |
Deferasirox |
34 |
A Multicenter, Open-label, Single Arm, Interventional Phase IV Study, to Evaluate the Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia |
Withdrawn |
NCT02069886 |
Phase 4 |
deferasirox |
35 |
Efficacy and Safety Study of Sugammadex in Children 0-2 Years Old |
Unknown status |
NCT03728543 |
Phase 2, Phase 3 |
Sugammadex |
36 |
Study of Safty and Efficacy of Adjuvant Vitamin c in Augmenting Iron Chelation |
Unknown status |
NCT02083575 |
Phase 2, Phase 3 |
Vitamin C, Defriprone, deferisarox;deferiprone , deferesarox |
37 |
Pharmacokinetics of Sofosbuvir and Ledipasvir in Hepatitis C Virus - Infected Adolescent Patients With Haematological Disorders |
Unknown status |
NCT04353986 |
Phase 3 |
Sofosbuvir and Ledipasvir |
38 |
Phase 2 Study of Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin. |
Unknown status |
NCT01624038 |
Phase 2, Phase 3 |
Hydroxyurea ,Epiao;hydroxyurea, blood transfusion |
39 |
Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients: A Prospective Pilot Study |
Unknown status |
NCT01016093 |
Phase 2, Phase 3 |
Zoledronic acid;Placebo |
40 |
Combined Therapy of Silymarin and Desferrioxamine in Patients With B-thalassemia Major: a Randomized Double-blind Clinical Trial |
Unknown status |
NCT00999349 |
Phase 2, Phase 3 |
Silymarin (LEGALON);Placebo |
41 |
A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload |
Unknown status |
NCT01511848 |
Phase 2, Phase 3 |
DFP (ferriprox) and deferasirox (ICL 670);DFP, DFO |
42 |
A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study |
Unknown status |
NCT02173951 |
Phase 2, Phase 3 |
Deferiprone |
43 |
Effect of Zinc Supplementation on Glucose Homeostasis in Patients With β-Thalassemia Major Complicated With Diabetes Mellitus |
Completed |
NCT03851055 |
Phase 3 |
Zinc |
44 |
Impact of Combination Therapy Between Hydroxy Urea, Omega 3, Nigella Sativa and Honey on Antioxidant-oxidant Status and Reduction of Iron Overload in Pediatric Major Thalassemia |
Completed |
NCT04292314 |
Phase 2, Phase 3 |
Omega 3;Nigella Sativa Oil;Hydroxyurea;Honey;Deferoxamine |
45 |
A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia |
Completed |
NCT02604433 |
Phase 3 |
Luspatercept |
46 |
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670)in β-thalassemia Patients With Transfusional Iron Overload |
Completed |
NCT00171210 |
Phase 3 |
Deferasirox |
47 |
A Study of Efficacy and Safety of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis |
Completed |
NCT00171171 |
Phase 3 |
deferasirox |
48 |
A Randomized, Comparative, Open Label Phase III Trial on Efficacy & Safety of Long-term Treatment With ICL670 Compared to Deferoxamine in Beta-thalassemia Patients With Transfusional Hemosiderosis |
Completed |
NCT00061750 |
Phase 3 |
ICL670;deferoxamine |
49 |
Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major |
Completed |
NCT01125254 |
Phase 2, Phase 3 |
Amlodipine |
50 |
Efficacy and Safety of Combination of Hydroxyurea and Low-dose Thalidomide on Hemoglobin Synthesis in Thalassemia Patients |
Completed |
NCT05132270 |
Phase 2, Phase 3 |
hydroxyurea and thalidomide |
|